Nishant C. Saxena net worth and biography

Nishant Saxena Biography and Net Worth

Mr. Saxena joined Corbus in May 2026. He has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he served as Chief Financial Officer at Jeune Aesthetics, Inc., a wholly owned subsidiary of Krystal Biotech, Inc. (NASDAQ: KRYS).

Previously, Mr. Saxena spent over 15 years at Evercore , most recently as a Managing Director in Evercore’s healthcare group.

What is Nishant C. Saxena's net worth?: The estimated net worth of Nishant C. Saxena is at least $641.90 thousand as of August 11th, 2026. Saxena owns 77,900 shares of Corbus Pharmaceuticals stock worth more than $641,896 as of September 11th. This net worth estimate does not reflect any other investments that Saxena may own. Learn More about Nishant C. Saxena's net worth.
How do I contact Nishant C. Saxena?: The corporate mailing address for Saxena and other Corbus Pharmaceuticals executives is 500 River Ridge Drive, Norwood MA, 02062. Corbus Pharmaceuticals can also be reached via phone at (617) 963-0100 and via email at [email protected]. Learn More on Nishant C. Saxena's contact information.
Has Nishant C. Saxena been buying or selling shares of Corbus Pharmaceuticals?: During the past quarter, Nishant C. Saxena has bought $25,038.00 of Corbus Pharmaceuticals stock. Most recently, on Tuesday, August 11th, Nishant C. Saxena bought 2,600 shares of Corbus Pharmaceuticals stock. The stock was acquired at an average cost of $9.63 per share, with a total value of $25,038.00. Following the completion of the transaction, the insider now directly owns 77,900 shares of the company's stock, valued at $750,177. Learn More on Nishant C. Saxena's trading history.
Who are Corbus Pharmaceuticals' active insiders?: Corbus Pharmaceuticals' insider roster includes Anne Altmeyer (Director), Yuval Cohen (CEO), Ian Hodgson (COO), John Jenkins (Director), Winston Kung (Director), Sean Moran (CFO), and Nishant Saxena (Insider). Learn More on Corbus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Corbus Pharmaceuticals?: During the last twelve months, Corbus Pharmaceuticals insiders bought shares 3 times. They purchased a total of 16,100 shares worth more than $126,243.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 115,641 shares worth more than $1,469,508.36. The most recent insider tranaction occured on August, 11th when insider Nishant C Saxena bought 2,600 shares worth more than $25,038.00. Insiders at Corbus Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Corbus Pharmaceuticals.
Information on this page was last updated on 8/11/2026.

Nishant C. Saxena Insider Trading History at Corbus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/11/2026	Buy	2,600	$9.63	$25,038.00	77,900
6/3/2026	Buy	9,000	$7.58	$68,220.00	75,300
6/2/2026	Buy	4,500	$7.33	$32,985.00	66,300

Nishant C. Saxena Buying and Selling Activity at Corbus Pharmaceuticals

Corbus Pharmaceuticals Company Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Today's Range

Now: $8.24

$8.21

$8.79

50 Day Range

MA: $9.79

$8.24

$11.48

2 Week Range

Now: $8.24

$7.12

$20.56

Volume

646,690 shs

Average Volume

606,303 shs

Market Capitalization

$153.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.63